The principal liabilities of the two marketed TZDs, rosiglitazone (Avandia; GlaxoSmithKline) and pioglitazone (Actos; Takeda/Eli Lilly), both introduced in 1999, are oedema and weight gain.
Some results have been hidden because they may be inaccessible to you